JNJ
NEW YORK STOCK EXCHANGE, INC. · Pharmaceuticals
Johnson & Johnson
$245.84
+3.35 (+1.38%)
JNJ News17 articles
J&J Shares Dip Amid $20B Orthopedics Unit Sale Talks, New Facility Investment
Johnson & Johnson shares fell following reports the company is exploring a sale of its DePuy Synthes orthopedics business for around $20 billion. The healthcare giant also committed over $1 billion to a new cell-therapy manufacturing plant in Pennsylvania.
J&J Shares Face Post-Holiday Pressure After Latest Talc Verdict
Johnson & Johnson shares closed lower Friday after a jury found the company liable in a baby powder cancer case, awarding $250,000. Investors await Tuesday's trading after the holiday, with the ex-dividend date approaching.
AbbVie Gains Ahead of Holiday; Investors Eye Pipeline and Pricing
AbbVie shares advanced 1.8% to $231.50 in Friday's session, outpacing peers. Trading volume was elevated as investors assess the company's strategic pivot and regulatory challenges.
Healthcare ETF Rises on Dexcom, Moderna Earnings; Markets Eye Holiday
Healthcare stocks advanced Friday, with the XLV ETF rising 1.1% as Dexcom and Moderna posted strong quarterly results. U.S. markets are closed Monday for the Presidents Day holiday.
J&J Stock Dips After $250K Talc Verdict, Eyes on Appeal and Dividend
Johnson & Johnson shares declined 0.45% Friday following a $250,000 verdict in a talc litigation case. The company intends to appeal, with markets closed Monday for the holiday.
Pfizer Shares Dip in Premarket Amid SEC Settlement, Partnership News
Pfizer stock edged lower in premarket trading following a $29 million SEC settlement agreement and a new biotech incubator partnership. Investors await key inflation data.
AbbVie Gains as Analyst Target Hike Meets Macroeconomic Caution
AbbVie shares advanced Tuesday after BNP Paribas Exane raised its price target, while broader markets were mixed as traders awaited delayed U.S. jobs and inflation data.
Boston Scientific Stock Rebounds on Positive Farapulse Data, CHAMPION-AF Trial Looms
Boston Scientific shares recovered slightly after a recent sell-off, supported by new long-term data for its Farapulse ablation system. Investor focus now shifts to the upcoming CHAMPION-AF trial results expected in late March.
JNJ Shares Hold Steady Amid Investor Conferences and Insider Activity
Johnson & Johnson shares traded near $238.70 as the company announced March investor conference appearances and an insider option exercise by Chief Technology & Risk Officer Kathryn Wengel.
Johnson & Johnson Shares Dip in Extended Trading Amid Healthcare Sector Weakness
Johnson & Johnson stock declined 0.6% in after-hours trading Monday as healthcare stocks underperformed the broader market. The company faces ongoing talc litigation and will present at an industry conference next month.
Johnson & Johnson Shares Retreat Amid Healthcare Sector Weakness
Johnson & Johnson stock declined 1.1% as healthcare stocks underperformed the broader market. Traders are eyeing upcoming U.S. jobs and inflation data for direction.
Merck Nears 52-Week Peak Amid Insider Sale, Investors Eye Pipeline Updates
Merck shares climbed 1.8% to $121.93, extending gains for a seventh session and approaching a 52-week high. An executive sold 37,685 shares as investors await the impact of 2026 guidance and pipeline developments.
Johnson & Johnson Stock Nears 52-Week High Amid Legal and Medical Device Updates
Johnson & Johnson shares approached a 52-week high as a New Jersey court disqualified a plaintiffs' firm from talc cases and the company reported positive pilot data for its atrial fibrillation platform.
JNJ Nears 52-Week Peak Amid Legal Win and Promising Heart Device Data
Johnson & Johnson shares approach a 52-week high after a New Jersey court disqualified a plaintiffs' firm from talc cases and the company released positive pilot data for its experimental atrial fibrillation platform.
Healthcare Sector Sees Divergence: Molina Plunges on Outlook, XLV Gains Amid Regulatory Warnings
Molina Healthcare plummeted 25.5% after slashing its 2026 profit forecast and announcing a Medicare Part D exit, while the Health Care Select Sector SPDR Fund (XLV) rose 1.8%. Regulatory warnings on compounded obesity drugs added pressure to the sector.
AbbVie Shares Gain 2% to Close Near $223 Amid Earnings Volatility, Credit Upgrade
AbbVie stock rose 2% Friday, ending a turbulent week marked by earnings scrutiny and a Moody's credit rating upgrade. Investors remain focused on Skyrizi and Rinvoq growth amid competitive pressures.
J&J Stock Rises as Court Disqualifies Talc Litigation Firm, AFib Device Data Released
Johnson & Johnson shares gained 0.9% following a New Jersey appeals court decision to remove Beasley Allen from state talc cases and the release of early 12-month data for its investigational AFib device.